RTSN

10.51019.22%
AD

Alexander Duke Schwartz

Chief Financial Officer

Mr. Alexander Duke Schwartz, also known as Alex, MBA., serves as Chief Financial Officer at Retension Pharmaceuticals, Inc. since April 2026. He was Senior Director of Investor Relations at Esperion Therapeutics, Inc. since May 2018. He held senior finance and investor relations roles at Allakos Inc. Prior to joining Esperion, Mr. Schwartz was a publishing analyst at Stifel, Nicolaus & Company, Incorporated, Research Division until May 2018. He was a trader at Schonfeld Securities. He most recently served as Vice President of Financial Planning & Analysis and Investor Relations at Ventyx Biosciences, Inc., which was acquired by Eli Lilly and Company in March 2026. He served as an Executive Director of Investor Relations at NGM Biopharmaceuticals, Inc. since August 2020 until August 2021. Mr. Schwartz got an MBA in finance from Boston College Carroll School of Management. and holds a B.S. in Finance from Indiana University’s Kelley School of Business.

Positions